Interferon gamma (IFNG) Antibody [IFNG/466]

• Type II interferon produced by immune cells such as T-cells and NK cells that plays crucial roles in antimicrobial, antiviral, and antitumor responses by activating effector immune cells and enhancing antigen presentation (PubMed:16914093, PubMed:8666937). Primarily signals through the JAK-STAT pathway after interaction with its receptor IFNGR1 to affect gene regulation (PubMed:8349687). Upon IFNG binding, IFNGR1 intracellular domain opens out to allow association of downstream signaling components JAK2, JAK1 and STAT1, leading to STAT1 activation, nuclear translocation and transcription of IFNG-regulated genes. Many of the induced genes are transcription factors such as IRF1 that are able to further drive regulation of a next wave of transcription (PubMed:16914093). Plays a role in class I antigen presentation pathway by inducing a replacement of catalytic proteasome subunits with immunoproteasome subunits (PubMed:8666937). In turn, increases the quantity, quality, and repertoire of peptides for class I MHC loading (PubMed:8163024). Increases the efficiency of peptide generation also by inducing the expression of activator PA28 that associates with the proteasome and alters its proteolytic cleavage preference (PubMed:11112687). Up-regulates as well MHC II complexes on the cell surface by promoting expression of several key molecules such as cathepsins B/CTSB, H/CTSH, and L/CTSL (PubMed:7729559). Participates in the regulation of hematopoietic stem cells during development and under homeostatic conditions by affecting their development, quiescence, and differentiation (By similarity).

• Vilcek J. Cytokine Growth Factor Rev 1997,8(4):239
• Farrar MA and Schreiber RD. Annu Rev Immunol 1993, 11:571-611
• Vilcek J., et al. Methods Enzymol 1986,119:48-54

• https://pubmed.ncbi.nlm.nih.gov/6180322/
• https://pubmed.ncbi.nlm.nih.gov/6173769/
• https://pubmed.ncbi.nlm.nih.gov/2860101/
• https://pubmed.ncbi.nlm.nih.gov/6329718/
• https://pubmed.ncbi.nlm.nih.gov/6176945/
• https://pubmed.ncbi.nlm.nih.gov/19054851/
• https://pubmed.ncbi.nlm.nih.gov/15489334/
• https://pubmed.ncbi.nlm.nih.gov/6427223/
• https://pubmed.ncbi.nlm.nih.gov/3109913/
• https://pubmed.ncbi.nlm.nih.gov/2504704/
• https://pubmed.ncbi.nlm.nih.gov/8349687/
• https://pubmed.ncbi.nlm.nih.gov/8163024/
• https://pubmed.ncbi.nlm.nih.gov/7729559/
• https://pubmed.ncbi.nlm.nih.gov/8666937/
• https://pubmed.ncbi.nlm.nih.gov/9643557/
• https://pubmed.ncbi.nlm.nih.gov/11112687/
• https://pubmed.ncbi.nlm.nih.gov/16914093/
• https://pubmed.ncbi.nlm.nih.gov/32163377/
• https://pubmed.ncbi.nlm.nih.gov/1902591/
• https://pubmed.ncbi.nlm.nih.gov/7617032/
• https://pubmed.ncbi.nlm.nih.gov/10860730/
• https://pubmed.ncbi.nlm.nih.gov/10986460/
• https://pubmed.ncbi.nlm.nih.gov/1525157/
• https://pubmed.ncbi.nlm.nih.gov/15327519/

There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.

3458

P01579

12q14

20-25kDa

Interferon gamma, Immune interferon, AMCF1; Beta thromboglobulin like protein; CXC chemokine ligand 8 (CXCL8); Emoctakin; Granulocyte chemotactic protein 1 (GCP1); IFG; IFI; IFN Immune; IFN-gamma (IFNG); Interleukin 8; Interferon gamma; LECT; LUCT; Lymphocyte derived neutrophil activating factor; LYNAP; Macrophage Activating Factor (MAF); Monocyte derived neutrophil activating protein (MONAP); Monocyte derived neutrophil chemotactic factor (MDNCF); Neutrophil activating factor (NAF); Neutrophil activating peptide 1 (NAP1); Neutrophil activating protein 1 (NAP1); SCYB8; T cell chemotactic factor; T Cell Interferon